Litcius/Paper detail

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

Ulrich Jaeger, Constantine S. Tam, Peter Borchmann, Joseph P. McGuirk, Marianne Johansen, Edmund K. Waller, Samantha Jaglowski, Charalambos Andreadis, S.R. Foley, Jason R. Westin, Isabelle Fleury, P. Joy Ho, Stephan Mielke, Takanori Teshima, Gilles Salles, Stephen J. Schuster, Fiona He, Richard T. Maziarz, Sebastian Mayer, Shinichi Makita, Marie José Kersten, Monalisa Ghosh, Nina D. Wagner‐Johnston, Koji Kato, Paolo Corradini, Hideki Goto, Silvia Colicino, Abhijit Agarwal, Chiara Lobetti‐Bodoni, Michael Bishop

2022Blood Advances18 citationsDOIOpen Access PDF

Topics & Concepts

Diffuse large B-cell lymphomaRefractory (planetary science)LymphomaMedicineTerm (time)OncologyInternal medicineCancer researchBiologyPhysicsAstrobiologyQuantum mechanicsCAR-T cell therapy researchVirus-based gene therapy researchIntegrated Circuits and Semiconductor Failure Analysis
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma | Litcius